Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.
Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback